Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Best dog photo

  • Selvita licensed its dual PIM/FLT3 inhibitor for acute myeloid leukemia pateints that’s currently in Phase I/II to Berlin-Chemie Menarini
  • GSK and Warp Drive Bio have partnered up to ‘drug the undraggable’ disease-associated proteins.

Andrei Kobylko

  • Following the FDA approval of Xadago last week, Newron has brought more good news form its schizophrenia candidate
  • AB Science‘s MS antibody has passed the non futility test in Phase III
  • Transgene has described its new generation of armed oncolytic viruses

Kuznetsov Alexey

  • Gilead is taking heat from various European humanitarian organisations over its Hep C blockbuster
  • FierceBiotech answered all (well, most of) our questions about Brexit this week
  • Novo Nordisk has resubmitted its NDA for fast-acting insulin aspart in the US — here’s more on its successor

Images from Andrei Kobylko, Best dog photo, colin rovers varndell, Kuznetsov Alexey / shutterstock.com

Previous post

Janssen Stops Phase II Trial for a Danish Blood Cancer Blockbuster

Next post

Meet this Year's Winner of the Startup Competition at BIO-Europe Spring